Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ADC Therapeutics SA
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 3, 2026
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
May 28, 2026
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
May 27, 2026
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
May 26, 2026
ADC Therapeutics Announces New Employee Inducement Grant
May 23, 2026
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
May 16, 2026
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
March 10, 2026
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
March 7, 2026
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
February 2, 2026
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
January 8, 2026
1
2
Next Page
→